Literature DB >> 28300326

HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases.

Prachi Matsye1,2, Lei Zheng1,2, Ying Si1,2, Soojin Kim1, Wenyi Luo3, David K Crossman4, Preston E Bratcher5, Peter H King1,4,5,6.   

Abstract

In neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), chronic activation of microglia contributes to disease progression. Activated microglia produce cytokines, chemokines, and other factors that normally serve to clear infection or damaged tissue either directly or through the recruitment of other immune cells. The molecular program driving this phenotype is classically linked to the transcription factor NF-κB and characterized by the upregulation of proinflammatory factors such as IL-1β, TNF-α, and IL-6. Here, we investigated the role of HuR, an RNA-binding protein that regulates gene expression through posttranscriptional pathways, on the molecular and cellular phenotypes of activated microglia. We performed RNA sequencing of HuR-silenced microglia and found significant attenuation of lipopolysaccharide-induced IL-1β and TNF-α inflammatory pathways and other factors that promote microglial migration and invasion. RNA kinetics and luciferase reporter studies suggested that the attenuation was related to altered promoter activity rather than a change in RNA stability. HuR-silenced microglia showed reduced migration, invasion, and chemotactic properties but maintained viability. MMP-12, a target exquisitely sensitive to HuR knockdown, participates in the migration/invasion phenotype. HuR is abundantly detected in the cytoplasmic compartment of activated microglia from ALS spinal cords consistent with its increased activity. Microglia from ALS-associated mutant SOD1 mice demonstrated higher migration/invasion properties which can be blocked with HuR inhibition. These findings underscore an important role for HuR in sculpting the molecular signature and phenotype of activated microglia, and as a possible therapeutic target in ALS and other neurodegenerative diseases.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  EAAT; Slc38a3; calyx of Held; system A; system N

Mesh:

Substances:

Year:  2017        PMID: 28300326     DOI: 10.1002/glia.23137

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  16 in total

Review 1.  RNA regulons in cancer and inflammation.

Authors:  Laura Simone Bisogno; Jack Donald Keene
Journal:  Curr Opin Genet Dev       Date:  2017-11-22       Impact factor: 5.578

2.  Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growth.

Authors:  Jiping Wang; Jianmei W Leavenworth; Anita B Hjelmeland; Reed Smith; Neha Patel; Ben Borg; Ying Si; Peter H King
Journal:  Glia       Date:  2019-08-10       Impact factor: 7.452

3.  Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells.

Authors:  Jiping Wang; Anita B Hjelmeland; L Burt Nabors; Peter H King
Journal:  Cancer Biol Ther       Date:  2019-04-16       Impact factor: 4.742

Review 4.  The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack.

Authors:  Abhishek Guha; Saboora Waris; Louis B Nabors; Natalia Filippova; Myriam Gorospe; Thaddaeus Kwan; Peter H King
Journal:  Adv Drug Deliv Rev       Date:  2021-12-16       Impact factor: 15.470

5.  SRI-42127, a novel small molecule inhibitor of the RNA regulator HuR, potently attenuates glial activation in a model of lipopolysaccharide-induced neuroinflammation.

Authors:  Rajeshwari Chellappan; Abhishek Guha; Ying Si; Thaddaeus Kwan; Louis B Nabors; Natalia Filippova; Xiuhua Yang; Anish S Myneni; Shriya Meesala; Ashley S Harms; Peter H King
Journal:  Glia       Date:  2021-09-17       Impact factor: 7.452

6.  Inhibition of the RNA Regulator HuR by SRI-42127 Attenuates Neuropathic Pain After Nerve Injury Through Suppression of Neuroinflammatory Responses.

Authors:  Robert E Sorge; Ying Si; Lyse A Norian; Abhishek Guha; Grace E Moore; L Burt Nabors; Natalia Filippova; Xiuhua Yang; Reed Smith; Rajeshwari Chellappan; Peter H King
Journal:  Neurotherapeutics       Date:  2022-07-21       Impact factor: 6.088

Review 7.  Understanding and targeting the disease-related RNA binding protein human antigen R (HuR).

Authors:  Christopher W Schultz; Ranjan Preet; Teena Dhir; Dan A Dixon; Jonathan R Brody
Journal:  Wiley Interdiscip Rev RNA       Date:  2020-01-23       Impact factor: 9.957

8.  Transgenic expression of HuR increases vasogenic edema and impedes functional recovery in rodent ischemic stroke.

Authors:  Agnieszka A Ardelt; Randall S Carpenter; Ifeanyi Iwuchukwu; An Zhang; William Lin; Ewa Kosciuczuk; Cyrus Hinkson; Tania Rebeiz; Sydney Reitz; Peter H King
Journal:  Neurosci Lett       Date:  2017-10-02       Impact factor: 3.046

9.  A Hydroxypyrone-Based Inhibitor of Metalloproteinase-12 Displays Neuroprotective Properties in Both Status Epilepticus and Optic Nerve Crush Animal Models.

Authors:  Jonathan Vinet; Anna-Maria Costa; Manuel Salinas-Navarro; Giuseppina Leo; Lieve Moons; Lutgarde Arckens; Giuseppe Biagini
Journal:  Int J Mol Sci       Date:  2018-07-25       Impact factor: 5.923

10.  Targeting the RNA-Binding Protein HuR Alleviates Neuroinflammation in Experimental Autoimmune Encephalomyelitis: Potential Therapy for Multiple Sclerosis.

Authors:  Vittoria Borgonetti; Maria Domenica Sanna; Laura Lucarini; Nicoletta Galeotti
Journal:  Neurotherapeutics       Date:  2020-11-16       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.